COLINZ.BO · BSE
COLINZ LABORATORIES LTD.
₹71.26
-4.99% (-₹3.74)
Prev. close
₹75
Volume
1,922
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About COLINZ LABORATORIES LTD.
Colinz Laboratories Limited manufactures and trades in pharmaceutical formulations in India. The company offers pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, ointments, injectables, creams, syrups, suppositories, etc.; and specialized products for gynaecology, cardiology, and gastroenterology, etc. Its allopathy products include oncology products, such as imitinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate, doxorubicin, filgrastim, pegylated liposome doxorubicin, etc.; antiritrovirals comprising lopinavir, indinavir, ritonavir, darunavir, zidovudine, lamivudin, and various combination therapy products; and products for other therapeutic areas, such as antibiotics, anti-fungals, anti-malarials, anti-virals, anti-manics, anti-convulsants, anti-migraines, anti-allergics, anthelmintics, anti-emetics, anti-inflammatory (NSAIDS), sedatives, cerebral activators, ulcer healing agents, laxatives, probiotics, digestive enzymes, topical steroids, ear/eye drops, hormones, sunscreens, vitamins, etc., as well as drugs used in protozoal infestations and neuropathy. In addition, the company offers ayurvedic products comprising anti-diarrhoeals, anti-pyretics, anti-inflammatories, anti-spasmodics, cough syrups, appetite stimulating agents, memory boosters, anti-piles, antacids, liver tonics, ulcer healing agents, digestive agents, uterine tonics, anti-diabetics, and general tonics, as well as drugs to treat oligospermia and erectile dysfunction. Further, it provides nutraceuticals, including spirulina tabs/caps, spirulina with vitamins and minerals, omega 3 fatty acids caps in softgel, codliver oil with vitamin caps in soft gel, amino acids tabs/caps, l-arginine with proantocyanidin granules, and hair growth formulations, etc., as well as collagen, glucosamine, and chondroitin tabs. Colinz Laboratories Limited was incorporated in 1986 and is based in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Dr. Narayanan Kutty Menon
Headquarters
Mumbai
Employees
62
Website
colinz.comExchange
View on BSE ↗Key stats
Market cap
₹18.89 Cr
P/E ratio (TTM)
6.8
EPS (TTM)
₹11.10
Beta (1Y · daily vs NIFTY 50)
0.27
Beta (5Y · monthly vs NIFTY 50)
1.37
Shares float
7.93 L
EPS · quarter ended Jun 2026
₹9.53
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹6.16 Cr | ₹6.97 Cr | ₹7.15 Cr | ₹7.03 Cr | ₹6.53 Cr | ₹6.14 Cr | |
| EBITDA | ₹52.28 L | ₹75.66 L | ₹78.10 L | ₹81.78 L | ₹79.30 L | ₹89.20 L |
| ₹20.80 L | ₹33.90 L | ₹45.17 L | ₹48.67 L | ₹49.66 L | ₹51.45 L | |
| Diluted EPS | ₹0.99 | ₹0.74 | ₹1.82 | ₹1.93 | ₹1.97 | ₹2.04 |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹10.23 Cr | ₹11.36 Cr | ₹11.82 Cr | ₹12.78 Cr | |
| — | — | ₹27.34 L | ₹56.98 L | ₹64.09 L | ₹38.99 L | |
| Stockholders' equity | — | — | ₹8.14 Cr | ₹8.95 Cr | ₹9.47 Cr | ₹10.04 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Current (short-term) debt, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹40.29 L | ₹1.03 Cr | ₹-1.45 Cr | ₹2.54 Cr | |
| Investing cash flow | — | — | ₹87,000 | ₹69,000 | ₹-23.43 L | ₹1.13 L |
| Financing cash flow | — | — | ₹11.11 L | ₹22.96 L | ₹23.80 L | ₹42.66 L |
| Capital expenditure | — | ₹-3.75 L | — | — | ₹-26.19 L | — |
| End cash position | — | — | ₹5.73 Cr | ₹7.00 Cr | ₹5.55 Cr | ₹8.53 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| COLINZ LABORATORIES LTD. | ₹18.89 Cr | ₹75 | 6.8 | 1.88 | 5.1% | 0.04 | -6.0% | +76.8% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 26
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.